Today's Top Health Care Stocks to Watch: PTC Therapeutics, Inovio Pharmaceuticals and Keryx Biopharmaceuticals

Today's top stories in health care and biotech.

May 23, 2014 at 8:46AM

Longview

Let's take a look at today's top stories in biotech and health care. Keep an eye out for PTC Therapeutics (NASDAQ:PTCT)Inovio Pharmaceuticals (NASDAQ:INO) and Keryx Biopharmaceuticals (NASDAQ:KERX)

PTC shares skyrocket after positive CHMP opinion for DMD drug
PTC shares are up over 100% in premarket this morning after the company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for its experimental Duchenne muscular dystrophy drug, or DMD, Translarna.  PTC is seeking a conditional approval for the drug as a potential treatment for DMD patients five years or older. According to the company, mid-stage clinical trial data showed a significant slowing of disease progression in DMD patients, helping them to perform better on the 6-minute walk test. 

Looking ahead, this positive opinion will help to form the basis for a potential conditional approval that will be decided on by the European Commission. If approved, Translarna will still need to complete an ongoing late-stage study that is designed to confirm the findings in the smaller mid-stage trial. 

Is this stock worth following after more than doubling this morning? If the current trend holds, PTC is in line to have a market cap of over $1 billion before the end of the day. That said, there is a dearth of pharmaceutical treatments for DMD patients, so it's quite possible that Translarna could sell very well if approved. As such, you may want to keep a close eye on this stock going forward.  

Inovio announces a reverse split, shares fall
Shares of Inovio are down around 3% in premarket this morning following an announcement that the company plans to initiate a 1 for 4 reverse split. According to the press release, the move was approved by both a majority of shareholders and Inovio's Board, with an effective date to be announced at a later time.

What's important to understand is that this split is being announced only a few weeks ahead of the planned top line data readout for VGX-3100, Inovio's experimental cervical cancer vaccine. Logistically, a split and a higher share price would probably do wonders in regards to institutional investment for this small-cap biotech, if the top line data are positive. Presently, institutions hold only 15% of Inovio's outstanding shares, which has probably played a big role in the tremendous volatility in the company's share price over the last year. 

On the flip side, a negative result for VGX-3100 would give the company room to raise funds for additional trials, without having to worry about potential delisting issues. In short, this is a smart move for the company, but its long-term consequences for shareholders won't be known until VGX-3100's data hit the Street.  

FDA extends Zerenex's PDUFA date
Shares of Keryx Biopharmaceuticals are down around 3% in premarket trading this morning after the FDA announced that it will extend the target action date for the company's experimental drug for chronic kidney disease called Zerenex. Specifically, the agency pushed the date back by three months to September 7, 2014. 

The reason investors are concerned this morning appears to be questions raised regarding the Chemistry, Manufacturing and Controls section of the New Drug Application, or NDA, for Zerenex. Because the agency deemed Keryx's response to these questions as a "major amendment", the agency said they will need additional time to review the changes.  

Is it time to panic? Frankly, I don't think so. It's not unusual for the FDA to change regulatory dates or require amendments to NDAs. We simply don't have much insight into the nature of the questions that triggered the revisions right now.

Will this stock be your next multi-bagger?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers